logo
Plus   Neg
Share
Email

Scout24 Stock Up On EUR 5.6 Bln Cash Offer From Hellman & Friedman, Blackstone

Shares of Scout24 AG were gaining around 12 percent in German trading after the operator of digital marketplaces specialising in real estate and automotive sectors announced its agreement to be acquired by Hellman & Friedman LLC and Blackstone Group L.P. (BX). The voluntary public takeover offer implies an equity value of Scout24 of approximately 4.9 billion euros and an enterprise value of approximately 5.7 billion euros.

In a statement, Scout24 said it has signed an investment agreement forming a strategic partnership with Pulver BidCo GmbH, jointly controlled by funds advised by Hellman & Friedman and affiliates of Blackstone.

Pulver BidCo will pursue the voluntary public takeover offer for all Scout24 shares with a price of 46 euros per share in cash.

The offer price represents about 27.4% premium to the unaffected share price of 36.1 euros on December 13, 2018, and about 24.4% premium to the unaffected 3-month-volume-weighted average share price.

The Takeover Offer will be subject to a minimum acceptance threshold of 50% plus one share.

Both Scout24's Management Board and Supervisory Board believe that the transaction is in the best interests of the company.

In Germany, Scout24 shares were trading at 46.42 euros, up 11.91 percent.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT